Katen Patel

PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA.

CollaGenex Pharmaceuticals, Inc. develops and markets innovative medical therapies to the dental and dermatology market. The company was founded in 1992 and is headquartered in Newtown, PA.

Alexo Therapeutics International develops immune-oncology therapies for cancer. The company is headquartered in South San Francisco, CA.

Mindrythm is a brain wellness company based in San Francisco, CA. Mindrythm develops medical technology to prevent neurological injury, with a focus on stroke prevention. The company's proprietary monitoring devices and communication platform aim to solve the triage problem in stroke, potentially saving more than 200,000 lives in 2022. The company was founded by John Keane and Paul Lovoi, with John Keane serving as the CEO since incorporation.

3CC Management LLC (Third Culture Capital) is a venture capital firm founded in 2020 by Julien L. Pham. The firm is headquartered in Boston, Massachusetts.

Vicept Therapeutics Inc. develops dermatologic therapeutic products. The firm develops topical agents for the treatment and prevention of a number of medical and cosmetic indications including bruising of the skin. The company was founded on July 1, 2009 by Neal Walker, Stewart D. Shanler, and Christopher V. Powala and is headquartered in Malvern, PA.

Vapogenix, Inc. operates as a clinical stage company which develops a new class of non-narcotic analgesics for localized pain. Its products are formulated volatile anesthetics; currently unformulated volatile anesthetics are used only as general anesthetics, by inhalation. The company was founded by Allen W. Burton, Phillip C. Phan and Danguole Spakevicius Altman in November 2007 and is headquartered in Houston, TX.

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA.

Meves Pharmaceuticals, Inc. provides pharmaceutical products and services. The company is headquartered in New York, NY.

Modis Therapeutics, Inc. is a biopharmaceutical company, which develops disease-modifying therapies for rare genetic diseases. Its product MT1621 is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. The company was founded by Peter H. Barber and Daniel D. DiPietro in 2016 and is headquartered in Oakland, CA.

H. Lee Moffitt Cancer Center & Research Institute, Inc. provides research & contributions to clinical trials, prevention and cancer control. The firm operates as National Cancer Institute (NCI) Comprehensive Cancer Center. The company was founded by Lee H. Moffitt in 1981 and is headquartered in Tampa, FL.